home / stock / igxt / igxt quote
Last: | $0.1785 |
---|---|
Change Percent: | 0.9% |
Open: | $0.178375 |
Close: | $0.1785 |
High: | $0.18 |
Low: | $0.1775 |
Volume: | 34,778 |
Last Trade Date Time: | 05/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.1785 | $0.178375 | $0.1785 | $0.18 | $0.1775 | 34,778 | 05-02-2024 |
$0.18 | $0.1772 | $0.18 | $0.18 | $0.17 | 191,667 | 05-01-2024 |
$0.16212 | $0.16 | $0.16212 | $0.1795 | $0.15363 | 165,658 | 04-30-2024 |
$0.16 | $0.17 | $0.16 | $0.17 | $0.14644 | 442,571 | 04-29-2024 |
$0.16396 | $0.1675 | $0.16396 | $0.18 | $0.1501 | 60,179 | 04-26-2024 |
$0.16664 | $0.1676 | $0.16664 | $0.18 | $0.15 | 149,612 | 04-25-2024 |
$0.15 | $0.15 | $0.15 | $0.169 | $0.15 | 81,018 | 04-24-2024 |
$0.1639 | $0.165 | $0.1639 | $0.165 | $0.13955 | 398,613 | 04-23-2024 |
$0.1699 | $0.175 | $0.1699 | $0.175 | $0.155 | 43,904 | 04-22-2024 |
$0.165 | $0.155 | $0.165 | $0.17025 | $0.155 | 53,282 | 04-19-2024 |
$0.17 | $0.175 | $0.17 | $0.175 | $0.165 | 73,325 | 04-18-2024 |
$0.16 | $0.18 | $0.16 | $0.18 | $0.155 | 47,480 | 04-17-2024 |
$0.18 | $0.17 | $0.18 | $0.18 | $0.164855 | 46,967 | 04-16-2024 |
$0.17 | $0.1631 | $0.17 | $0.173 | $0.1631 | 36,604 | 04-15-2024 |
$0.1851 | $0.1773 | $0.1851 | $0.1851 | $0.1631 | 71,484 | 04-12-2024 |
$0.18035 | $0.19 | $0.18035 | $0.19 | $0.1773 | 33,415 | 04-11-2024 |
$0.187 | $0.1835 | $0.187 | $0.19 | $0.1835 | 28,205 | 04-10-2024 |
$0.18026 | $0.174 | $0.18026 | $0.1844 | $0.163 | 138,268 | 04-09-2024 |
$0.174 | $0.16015 | $0.174 | $0.174 | $0.1553 | 71,125 | 04-08-2024 |
$0.169 | $0.19 | $0.169 | $0.19 | $0.168 | 438,100 | 04-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Intelgenx Techs Corp Company Name:
IGXT Stock Symbol:
OTCMKTS Market:
SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast VersaFilm ® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (...
SAINT LAURENT, Quebec, April 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC (“Xiromed”), has receive...
SAINT LAURENT, Quebec, March 21, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "Int...